Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Sunshine Biopharma (SBFM) over the last 12 years, with Q3 2025 value amounting to $65355.0.

  • Sunshine Biopharma's Non Operating Income fell 4719.51% to $65355.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$33399.0, marking a year-over-year decrease of 10417.14%. This contributed to the annual value of $443147.0 for FY2024, which is 3429.22% down from last year.
  • Latest data reveals that Sunshine Biopharma reported Non Operating Income of $65355.0 as of Q3 2025, which was down 4719.51% from $74655.0 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Non Operating Income ranged from a high of $946747.0 in Q4 2021 and a low of -$4.9 million during Q1 2021
  • Over the past 5 years, Sunshine Biopharma's median Non Operating Income value was $89141.0 (recorded in 2024), while the average stood at -$431485.2.
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 858012.73% in 2021, then skyrocketed by 144282.05% in 2023.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Non Operating Income stood at $946747.0 in 2021, then plummeted by 91.06% to $84599.0 in 2022, then surged by 86.13% to $157464.0 in 2023, then tumbled by 258.28% to -$249227.0 in 2024, then surged by 126.22% to $65355.0 in 2025.
  • Its Non Operating Income was $65355.0 in Q3 2025, compared to $74655.0 in Q2 2025 and $75818.0 in Q1 2025.